Marker Therapeutics is a clinical-stage immuno-oncology company developing T cell-based cancer therapies. Marker's core technology is its Multi Antigen Recognizing T cell (MAR-T) platform, which expands naturally occurring T cells from a patient's or donor's blood that are already capable of recognizing multiple tumor-associated antigens — up to six simultaneously. Unlike CAR-T therapies, MAR-T cells are not genetically engineered. Marker's primary target population is cancer patients who have already failed other therapies, including those who relapsed after CAR-T. Marker has two product candidates: MT-601, an autologous (patient-derived) MAR-T therapy being studied in relapsed lymphoma and pancreatic cancer; and MT-401-OTS, a pre-manufactured off-the-shelf product derived from healthy donor blood, being studied in AML and MDS. Marker is pre-revenue and funds operations through grants from CPRIT and the NIH, and equity raises. The path to revenue is FDA approval of one or more MAR-T candidates. If approved, MT-601 would likely be sold per-patient to hospitals at pricing similar to CAR-T therapies, while MT-401-OTS's shared manufacturing model could enable lower per-dose costs. Marker licenses its core technology from Baylor College of Medicine under an exclusive worldwide license, and outsources manufacturing to CDMOs.